Office of the Nursing & Midwifery Services Director

Seirbhís Sláinte Níos Fearr á Forbairt | Building a Better Health Service

Continuous Professional Education Programme for Registered Nurses and Midwives

to administer

Priorix or MMRvaxPro Vaccine

under the Medicine Protocol to children/students in Primary and/or Second Level Schools through a School Immunisation Programme

(second level for outbreak administration)

Medicine Protocol

This Medicine Protocol is a specific written instruction for the administration of measles, mumps and rubella (live) vaccine

(Priorix or MMRvaxPro)

to groups of children/student who may not be individually identified before presentation for treatment.

Clinical Criteria

Active immunisation against and prevention of measles, mumps and rubella infection.

Circumstances in which the Medicine Protocol applies

- The Schools Immunisation Programme is delivered annually by the HSE.

- The aim of the immunisation programme is to complete the measles, mumps and rubella vaccine, (live) two dose schedule for children

  -1st dose at 12 months

  -2nd dose in junior infants

- **Please note:** If the 1st dose of Priorix / MMRvaxPro vaccine is given to a child in junior infants or age equivalent under this Medicine Protocol, a 2nd dose of MMR should be given at least four weeks later at a mop-up clinic.

- This Medicine Protocol also applies in MMR catch-up campaigns and outbreak situations as recommended by NIAC, (2017)

Inclusion Criteria for MMRvaxPro / Priorix

- Children/students in primary/second level schools or age equivalent

  (e.g. home schooled, special school).

- Children/students with a valid consent.

Exclusion Criteria for MMRvaxPro / Priorix

- Any child/student who has had an **anaphylactic or hypersensitivity** reaction to a previous dose of Priorix/MMRvaxPRo or any of its components including neomycin or gelatin (refer to protocol).

- **Acute febrile illness.** The presence of a minor infection such as a mild upper respiratory infection or low grade fever is not a contraindication for immunisation.

- History of **thrombocytopenia** within six weeks of receiving MMR vaccine.

- **Contraindication to intramuscular injection** (haematological disorder/coagulation disorder)

Exclusion Criteria

- Immunocompromised children/student either due to disease or treatment.
- Active untreated tuberculosis

- **Children/Students who received**:
- low-dose immunoglobulin within the previous 5 months
- red-cell transfusion within 6 months
- high-dose immunoglobulin within 11 months.
- Varicella or Yellow Fever live vaccines within the previous 4 weeks.

- **Pregnancy** where applicable.

Note

- Child/student on topical **tacrolimus** within the last 28 days is NOT a contraindication to MMR (NIAC 2018).

Priorix Vaccine: Product Information

- Details of the most current and update information of the SmPC and other data is available on the website:

https://www.hpra.ie

What are the constituents of Priorix Vaccine?

- After reconstitution, **Priorix** (0.5 ml) contains:

- Live attenuated measles vaccine (Schwarz strain)[1]
- Live attenuated mumps virus (RIT 4385 strain)[2]
- Live attenuated rubella virus (Wistar RA 27/3 strain) [3]

- [1]Produced in chick embryo cells
- [2]Produced in human diploid (MRC-5) cells
- [3]Cell Culture Infective Dose 50%

For a full list of excipients please see:
https://www.hpra.ie

Nature and contents of pack:

- Priorix comes in packs of 10
- MMR component (powder) in vial (Type I glass) with rubber stopper and 0.5 ml of solvent for solution in pre filled syringe (Type I glass) with a rubber plunger stopper.
- Unattached needles of 25mm X 2
- **Prior to reconstitution** the lyophilised MMR component is a **white to slightly pink powder** and the **solvent is a clear**, colourless solution.
- The reconstituted vaccine may vary in colour from **clear peach to fuchsia pink**.

MMRvaxPro Vaccine: Product Information

- Details of the most current and update information of the SmPC and other data is available on the website: **https://www.hpra.ie**

What are the constituents of MMRvaxPro Vaccine?

For a full list of excipients please see

https://www.hpra.ie

Nature and Contents of Pack:

- Powder in a Vial (Type1 glass) with a stopper (butyl rubber)
- Solvent in a pre-filled syringe (Type1 glass) with plunger stopper (chlorobutyl rubber) and tip cap (styrene-butadienerubber).
- MMRvaxPro is available in one single dose vial (powder) and one single dose 0.5 ml pre-filled syringe (solvent) with two unattached needles.

Possible Side Effects

- **Very common** **(more than 1 per 10 doses of vaccine):**
- Redness at injection site.
- Fever >38˚c

- **Common** **(more than 1 in 100 doses and less than 1 in 10 doses)**
- Rash
- Pain and swelling at injection site
- Fever >39˚c
- Upper respiratory tract infection

  - **For a full list of side effects refer to https://www.hpra.ie**

Possible Side Effects

Uncommon

(>1 in 1000 and <1 in 100):

- Nasal congestion and sore throat*;*
- Upper respiratory tract infection or viral infection;
- runny nose.
- • Diarrhoea, vomiting.
- • Hives.
- • Injection-site rash.
-

Rare

(>1 in 10,000 - < 1 in 1,000):

- Febrile convulsions
- Allergic reactions
- Mumps-like condition (‘mini-mumps’) with swelling of testicles and salivary glands 3 weeks post vaccination
- Measles-like condition (‘mini-measles’) with mild pyrexia and rash 6-10 days post MMR.
- Rubella-like condition with lymph node swelling, arthralgia and rash 2-4 weeks post vaccination.
- Thrombocytopenia-1 in 25,000 within 6 weeks from MMR

Any Questions?